Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA3 | P07451 | 3/20 | 0.53 |
| ▸ | CA4 | P22748 | 3/20 | 0.53 |
| ▸ | CA6 | P23280 | 3/20 | 0.53 |
| ▸ | CA5A | P35218 | 3/20 | 0.53 |
| ▸ | CA7 | P43166 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.53 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728401 | 1.00 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| Hydrochloric Acid SCHEMBL27910221 | 0.98 | KDM4E (0.51) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL7615406 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL7615401 | 0.96 | KDM4E (0.53) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL13797243 | 0.93 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL30567327 | 0.93 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL20681307 | 0.93 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL30263749 | 0.93 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL30207038 | 0.93 | KDM4E (0.56) | KDM4EALDH1A1HSD17B10CA12CA1 | |
| SCHEMBL8765796 | 0.88 | ALDH1A1 (0.45) | KDM4EALDH1A1HSD17B10CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921559-B2 | 4-substituted-cyclohexylamino-4-piperidinyl-acetamide antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-30 | — | — | US | disclosed |
| EP-2646429-B1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2646429-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | Janssen Pharmaceutica, N.V. (BE) | 2013-10-09 | — | — | EP | disclosed |
| EP-2635572-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | Senomyx, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061698-A9 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012075115-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-07 | — | — | US | disclosed |
| WO-2012061698-A2 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | SENOMYX, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-7795310-B2 | Methods and reagents for the treatment of metabolic disorders | COMBINATORX, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| EP-1781303-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF METABOLIC DISORDERS | COMBINATORX INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-6043252-A | A POTENT AND SELECTIVE INHIBITORS OF CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE SPECIFIC PHOSPHODIESTERASE (CGMP-SPECIFIC PDE); TREATING CARDIOVASCULAR DISORDERS AND ERECTILE DYSFUNCTION | ICOS CORPORATION (US) | 2000-03-28 | — | — | US | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0912567-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997043287-A1 | CARBOLINE DERIVATIVES | ICOS CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| US-RE32944-E | Aromatic carboxylic amide derivatives | Kissei Yakuhin Kogyo Kabushiki (JP) | 1989-06-06 | — | — | US | disclosed |
| US-4078066-A | HYPOTENSIVE AGENTS, SURFACTANTS, BACTERICIDES AND WATER SOFTENERS | E. R. SQUIBB & SONS, INC. (US) | 1978-03-07 | — | — | US | disclosed |
| US-4033971-A | HYPOTENSIVES, SURFACTANTS, BACTERICIDES, WATER SOFTENERS | E. R. SQUIBB & SONS, INC. (US) | 1977-07-05 | — | — | US | disclosed |
| US-4026896-A | ANTIALLERGENS | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (KISSEI PHARMACEUTICAL CO. LTD.) (JA) | 1977-05-31 | — | — | US | disclosed |
| US-3940422-A | ANTIALLERGEN | KISSEI YAKUHIN KOGYO KABUSHIKI KAISHA (JA) | 1976-02-24 | — | — | US | disclosed |
| US-3936465-A | SURFACTANT, WATER SOFTENER, BACTERICIDE, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142733-A1 | 4-SUBSTITUTED-CYCLOHEXYLAMINO-4-PIPERIDINYL-ACETAMIDE ANTAGONISTS OF CCR2 | CCR2, CCR5, CCR1 | KDM4E 1448/4885ALDH1A1 298/4885HSD17B10 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.